OKYO Pharma Limited Result of Meeting (3079Y)
03 May 2023 - 10:00PM
UK Regulatory
TIDMOKYO
RNS Number : 3079Y
OKYO Pharma Limited
03 May 2023
3 May 2023
OKYO Pharma Limited
("OKYO" or "Company")
Result of General Meeting
The board of directors of OKYO Pharma Limited (LSE: OKYO;
NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company
which is developing OK-101 to treat dry eye disease to address the
significant unmet need in this multi-billion-dollar market, is
pleased to announce that at the General Meeting ("GM") of the
Company held earlier today all resolutions were duly passed.
The result of the poll, including the proxy voting, is as
follows:
For Against Discretion Withheld For + discretion
Resolution Description Votes % Votes Votes % Votes Total Votes %
Votes % Votes Votes Votes
Cast Votes Cast Cast Cast
Cast (excl.
Votes
Withheld)
--------------- ------------ ------ -------- ------- ------- ------- --------- ------------ ------------ -------
SHARE
RES:001 CONSOLIDATION 545,538,277 99.93 375,103 0.07 32,915 0.006 60,371 545,946,295 545,571,192 99.93
--------------- ------------ ------ -------- ------- ------- ------- --------- ------------ ------------ -------
DIRECTORS
TO ALLOT
RES:002 SHARES 545,533,344 99.92 378,836 0.07 32,915 0.006 61,571 545,945,095 545,566,259 99.93
--------------- ------------ ------ -------- ------- ------- ------- --------- ------------ ------------ -------
PRE-EMPTION
RES:003 RIGHTS 545,527,392 99.92 384,788 0.07 32,915 0.006 61,571 545,945,095 545,560,307 99.93
--------------- ------------ ------ -------- ------- ------- ------- --------- ------------ ------------ -------
AMENDMENT
RES:004 TO ARTICLES 545,327,392 99.93 375,103 0.07 32,915 0.006 71,256 545,735,410 545,360,307 99.93
--------------- ------------ ------ -------- ------- ------- ------- --------- ------------ ------------ -------
Further information on votes:
As at 2 May 2023 , there were 1,658,792,349 ordinary shares in
issue. Shareholders are entitled to one vote per ordinary share.
Any vote withheld is not a vote in law and so has not been included
in the calculation of the proportion of votes for and against any
Resolution.
The resolutions were all passed on a poll, with votes cast in
accordance with proxy voting instructions submitted to the Company
by the relevant deadline, together with those cast at the GM
itself, and will be available on the National Storage Mechanism,
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The result of poll and proxy voting will also be available on
the Company's website, www.okyopharma.com .
Enquiries:
Gary S. Jacob, Chief Executive +44 (0)20 7495
OKYO Pharma Limited Officer 2379
+44 (0)20 7495
Investor Relations Paul Spencer 2379
Optiva Securities
Limited +44 (0)20 3981
(Broker) Robert Emmet 4173
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMBBGDUIUGDGXX
(END) Dow Jones Newswires
May 03, 2023 08:00 ET (12:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024
